You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Non Squamous cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Advanced Lung Squamous Cell Carcinoma

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • No treatment is included in this study
  • Changsha, Hunan, China
    Yongchang Zhang
Aug 11, 2023

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)

Not yet recruiting
  • Advanced Squamous Non Small Cell Lung Cancer
  • AK112, Carboplatin, Paxlitaxel
  • Tislelizumab, Carboplatin, Paxlitaxel
  • (no location specified)
Apr 21, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer Trial in Boise (30% ascorbic acid in DMSO)

Recruiting
  • Squamous Cell Cancer
  • +3 more
  • 30% ascorbic acid in DMSO
  • Boise, Idaho
    Center for Biomedical Research,Inc.
Jul 2, 2023

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 17, 2023

Prognostic Immune Biomarkers in HNSCC

Completed
  • Head and Neck Cancer
  • Squamous Cell Carcinoma
  • Tumour immunoprofile evaluation
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Jul 3, 2023

Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)

Not yet recruiting
  • Advanced Squamous Non-Small-Cell Lung Cancer
  • (no location specified)
Jun 11, 2023

Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Tumors Trial in Melbourne

Not yet recruiting
  • Cutaneous Squamous Cell Carcinoma
  • +3 more
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
May 17, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only

Not yet recruiting
  • PARP Inhibitor for Esophageal Squamous Cell Carcinoma
  • Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
  • (no location specified)
Sep 24, 2023

NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
  • Wuhan, Hubei, China
    Union hospital
Feb 20, 2023

Carcinoma, Squamous Cell of Head and Neck, NSCLC, Ovarian Tumors Trial (disitamab vedotin)

Not yet recruiting
  • Carcinoma, Squamous Cell of Head and Neck
  • +3 more
  • disitamab vedotin
  • (no location specified)
Aug 15, 2023

Oral Cavity Squamous Cell Carcinoma Trial in San Francisco (NisinZ® P, Surgery (non-interventional, standard of care))

Not yet recruiting
  • Oral Cavity Squamous Cell Carcinoma
  • NisinZ® P
  • Surgery (non-interventional, standard of care)
  • San Francisco, California
    University of California, San Francisco
Oct 18, 2023

NSCLC Trial in Chongqing (procedure, drug, radiation)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • bronchial artery interventional therapy
  • +3 more
  • Chongqing, Chongqing, China
    Daping Hospital, Third Military Medical University
May 27, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

NSCLC Trial in Pittsburgh (M1774, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Cancer Center
May 22, 2023

The Long Non Coding MALAT1 asPotential Salivary Diagnostic

Completed
  • Oral Cancer Biomarkers
    • Giza, Egypt
      Rania Hassan Shalby
    Jan 31, 2023

    Non-squamous NSCLC Trial in Nanjing (paclitaxel polymeric micelles for injection)

    Not yet recruiting
    • Non-squamous NSCLC
    • paclitaxel polymeric micelles for injection
    • Nanjing, Jiangsu, China
    • +1 more
    Mar 13, 2023

    NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Feb 16, 2023

    Esophageal Squamous Cell Carcinoma, Chemo Effect, Side Effect of Drug Trial in Nanjing (Consolidation chemo (4 courses),

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • +2 more
    • Consolidation chemotherapy (4 courses)
    • Concurrent chemotherapy (2 courses)
    • Nanjing, Jiangsu, China
      The First Affiliated Hospital of Nanjing Medical University
    Mar 16, 2023

    Non-squamous NSCLC Trial (biological, drug, dietary supplement)

    Not yet recruiting
    • Non-squamous NSCLC
    • Pembrolizumab
    • +7 more
    • (no location specified)
    Feb 20, 2023

    NSCLC, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma Trial (QEQ278)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +3 more
    • QEQ278
    • (no location specified)
    Jul 14, 2022